Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Finished Goods (2023 - 2025)

Cytosorbents' Finished Goods history spans 3 years, with the latest figure at $3.5 million for Q4 2025.

  • Quarterly results put Finished Goods at $3.5 million for Q4 2025, up 112.53% from a year ago — trailing twelve months through Dec 2025 was $3.5 million (up 112.53% YoY), and the annual figure for FY2025 was $3.5 million, up 112.53%.
  • Finished Goods for Q4 2025 was $3.5 million at Cytosorbents, up from $2.3 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $3.5 million in Q4 2025 to a low of $1.7 million in Q4 2024.
  • The 3-year median for Finished Goods is $2.1 million (2023), against an average of $2.3 million.
  • The sharpest move saw Finished Goods fell 10.33% in 2024, then skyrocketed 112.53% in 2025.
  • Year by year, Finished Goods stood at $1.9 million in 2023, then dropped by 10.33% to $1.7 million in 2024, then soared by 112.53% to $3.5 million in 2025.
  • According to Business Quant data, Finished Goods over the past three periods came in at $3.5 million, $2.3 million, and $2.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.